Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer
Yizhen Pang, Long Zhao, Qihang Shang, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2021) Vol. 49, Iss. 4, pp. 1322-1337
Closed Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease
Yuriko Mori, Katharina Dendl, Jens Cardinale, et al.
Radiology (2023) Vol. 306, Iss. 2
Closed Access | Times Cited: 145
Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review
Liang Zhao, Jianhao Chen, Yizhen Pang, et al.
Theranostics (2022) Vol. 12, Iss. 4, pp. 1557-1569
Open Access | Times Cited: 112
Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond
Mengting Li, Muhsin H. Younis, Yongxue Zhang, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2022) Vol. 49, Iss. 8, pp. 2844-2868
Open Access | Times Cited: 74
FAPI-avid nonmalignant PET/CT findings: An expedited systematic review
Morten Bentestuen, Noor Al-Obaydi, Helle D. Zacho
Seminars in Nuclear Medicine (2023) Vol. 53, Iss. 5, pp. 694-705
Open Access | Times Cited: 40
Non-oncologic incidental uptake on FAPI PET/CT imaging
Masatoshi Hotta, Angela C. Rieger, Mahbod G Jafarvand, et al.
British Journal of Radiology (2022) Vol. 96, Iss. 1142
Open Access | Times Cited: 55
PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using68Ga-FAP-2286: Comparison with18F-FDG and68Ga-FAPI-46 in a Single-Center, Prospective Study
Yizhen Pang, Liang Zhao, Tinghua Meng, et al.
Journal of Nuclear Medicine (2022) Vol. 64, Iss. 3, pp. 386-394
Open Access | Times Cited: 53
The added value of [68Ga]Ga-DOTA-FAPI-04 PET/CT in pancreatic cancer: a comparison to [18F]F-FDG
Qiufang Liu, Si Shi, Shuai Liu, et al.
European Radiology (2023) Vol. 33, Iss. 7, pp. 5007-5016
Closed Access | Times Cited: 23
18F-FAPI-04 Outperforms18F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma
Xiang Li, Na Lu, Lili Lin, et al.
Journal of Nuclear Medicine (2024) Vol. 65, Iss. 2, pp. 206-212
Open Access | Times Cited: 11
Fibroblast Activation Protein Inhibitor Tracers and Their Preclinical, Translational, and Clinical Status in China
Liang Zhao, Fei Kang, Yizhen Pang, et al.
Journal of Nuclear Medicine (2024) Vol. 65, Iss. Supplement 1, pp. 4S-11S
Closed Access | Times Cited: 8
Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides
Richard P. Baum, Emil Novruzov, Tianzhi Zhao, et al.
Seminars in Nuclear Medicine (2024) Vol. 54, Iss. 4, pp. 537-556
Closed Access | Times Cited: 8
Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma or a Metaphor for Heterogeneity: From Single-Cell Analysis to Whole-Body Imaging
Rita Saúde-Conde, Ayça Arçay, Kosta Stosic, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 591-591
Open Access | Times Cited: 6
68Ga-DOTA-FAPI-04 and 18F-FDG PET/CT: a head-to-head comparison for peritoneal carcinomatosis diagnostic accuracy
Xiaolin Chen, Xiao Pan Pang, Yan Zhao, et al.
Abdominal Radiology (2025)
Closed Access
[18F]F-FAPI-42 PET dynamic imaging characteristics and multiparametric quantification of lung cancer: an exploratory study using uEXPLORER PET/CT
Lijuan Wang, Xiaojuan Pan, Shimin Ye, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2025)
Closed Access
Impact of 68Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With Digestive System Tumors
Aleksander Kosmala, Sebastian E. Serfling, Wiebke Schlötelburg, et al.
Clinical Nuclear Medicine (2022) Vol. 48, Iss. 1, pp. 35-42
Open Access | Times Cited: 27
The Superiority of Fibroblast Activation Protein Inhibitor (FAPI) PET/CT Versus FDG PET/CT in the Diagnosis of Various Malignancies
Yanzhao Dong, Haiying Zhou, Ahmad Alhaskawi, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1193-1193
Open Access | Times Cited: 18
Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics—Where We Are at and Where We Are Heading: A Systematic Review
Marko Magdi Abdou Sidrak, Maria Silvia De Feo, Ferdinando Corica, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3863-3863
Open Access | Times Cited: 16
Head-to-head comparison of [68Ga]Ga-FAPI PET and [18F]FDG PET in the detection of bone and lymph node metastasis in various cancers: A systematic review and meta-analysis
Guiyou Wu, Daofeng Wang, Wupeng Zhang, et al.
European Journal of Radiology (2024) Vol. 171, pp. 111302-111302
Closed Access | Times Cited: 5
Current research topics in FAPI theranostics: a bibliometric analysis
Andor F. van den Hoven, Ruth G.M. Keijsers, Marnix G. E. H. Lam, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2022) Vol. 50, Iss. 4, pp. 1014-1027
Closed Access | Times Cited: 25
FAPI PET versus FDG PET, CT or MRI for Staging Pancreatic-, Gastric- and Cholangiocarcinoma: Systematic Review and Head-to-Head Comparisons of Diagnostic Performances
Sophie E. M. Veldhuijzen van Zanten, Kay Pieterman, Bas P. L. Wijnhoven, et al.
Diagnostics (2022) Vol. 12, Iss. 8, pp. 1958-1958
Open Access | Times Cited: 21
Evaluation of the Diagnostic Accuracy of FAPI PET/CT in Oncologic Studies: Systematic Review and Metaanalysis
Grayson Wass, Kari Clifford, Rathan M. Subramaniam
Journal of Nuclear Medicine (2023) Vol. 64, Iss. 8, pp. 1218-1224
Open Access | Times Cited: 12
68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the68Ga-FAPI PET Observational Trial
Lukas Kessler, Nader Hirmas, Kim M. Pabst, et al.
Journal of Nuclear Medicine (2023) Vol. 64, Iss. 12, pp. 1910-1917
Open Access | Times Cited: 12
Comparison of 68Ga-FAPI and 18F-FDG PET/CT for the diagnosis of primary and metastatic lesions in abdominal and pelvic malignancies: A systematic review and meta-analysis
Xue Liu, Huiting Liu, Cailiang Gao, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11
From basic research to clinical application: targeting fibroblast activation protein for cancer diagnosis and treatment
Zeyu Zhang, Jinxin Tao, Jiangdong Qiu, et al.
Cellular Oncology (2023) Vol. 47, Iss. 2, pp. 361-381
Closed Access | Times Cited: 11
Fibroblast Activation Protein–Targeted PET/CT with18F-Fibroblast Activation Protein Inhibitor-74 for Evaluation of Gastrointestinal Cancer: Comparison with18F-FDG PET/CT
Weizhi Xu, Jiayu Cai, Peng Tianxing, et al.
Journal of Nuclear Medicine (2023) Vol. 65, Iss. 1, pp. 40-51
Open Access | Times Cited: 10
From Automated Synthesis to In Vivo Application in Multiple Types of Cancer—Clinical Results with [68Ga]Ga-DATA5m.SA.FAPi
Lukas Greifenstein, Carsten S. Kramer, Euy Sung Moon, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 8, pp. 1000-1000
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top